Recombinant bovine adenovirus is being developed as a live vector for animal vaccination and for human gene therapy. In this study, two replication-competent bovine adenovirus 3 (BAV-3) recombinants (BAV331 and BAV338) expressing bovine viral diarrhea virus (BVDV) glycoprotein E2 in the early region 3 (E3) of BAV-3 were constructed. Recombinant BAV331 contains chemically synthesized E2 gene (nucleotides modified to remove internal cryptic splice sites) under the control of BAV-3 E3/major late promoter (MLP), while recombinant BAV338 contains original E2 gene under the control of human cytomegalovirus immediate early promoter. Since E2, a class I membrane glycoprotein, does not contain its own signal peptide sequence at the 5Ј end, the bovine herpesvirus 1 (BHV-1) glycoprotein D signal sequence was fused in frame to the E2 open reading frame (ORF) for proper processing of the E2 glycoprotein in both the recombinant viruses. Recombinant E2 protein expressed by BAV331 and BAV338 recombinant viruses was recognized by E2-specific monoclonal antibodies as a 53-kDa protein, which also formed dimer with an apparent molecular weight of 94 kDa. Insertion of an E2-expression cassette in the E3 region did not effect the replication of recombinant BAV-3s. Intranasal immunization of cotton rats with these recombinant viruses generated E2-specific IgA and IgG responses at the mucosal surfaces and in the serum. In summary, these results show that the pestivirus glycoprotein can be expressed efficiently by BAV-3. In addition, mucosal immunization with replication-competent recombinant bovine adenovirus 3 can induce a specific immune response against the expressed antigen.
INTRODUCTION
Bovine viral diarrhea virus (BVDV) is a ubiquitous pathogen of cattle, causing significant economic losses. BVDV belongs to the genus pestivirus and contains a single-stranded, positive-sense RNA molecule, 12.5 kb in size (Renard et al., 1985) . The RNA has a single open reading frame (ORF) that encodes a number of structural and nonstructural peptides that are cotranslationally and posttranslationally cleaved from polyprotein precursors (Collett et al., 1988a,b) . Three putative BVDV structural glycoproteins named E ms (gp44-48), E1 (gp25), and E2 (gp53) were previously described (Thiel et al., 1991) . E2 is a glycoprotein of 51 to 58 kDa in molecular weight (Donis and Dubovi, 1987) , which induces strong neutralizing antibodies (Donis et al., 1988) .
Seroepidemiological studies have shown that most cattle contract BVDV infection during their lifetime. Currently, inactivated and modified-live (MLV) vaccines are used to protect cattle from BVDV infection (Bolin, 1995) . However, both types of vaccines have significant shortcomings. The major problem with MLV vaccines is that they are a potential source of in utero infection and/or immunosuppression (Liess et al., 1984; Roth and Kaeberle, 1983) . Since MLV vaccines need to replicate in the host, they are also susceptible to interference by maternal antibodies (Schultz, 1993) . Thus, the use of immunodominant BVDV proteins holds promise for the development of efficacious vaccines for the control of BVDV. Glycoprotein E2 of BVDV has been successfully expressed in a number of expression systems, such as baculovirus (Kweon et al., 1997) , bovine herpesvirus 1 (BHV-1) (Schmitt et al., 1999) , and fowlpox vectors (Elahi et al., 1999a) ; in addition, the E2 gene has been used in DNA immunization (Harpin et al., 1999) .
We have characterized bovine adenovirus 3 (BAV-3) (Reddy et al., , 1999a Idamakanti et al., 1999; Baxi et al., 1999) with the aim to develop it as an ideal vector for animal vaccination and gene therapy. BAV-3 was chosen because of its low pathogenicity, species specificity, and ability of the virus to grow to high titers in cell culture. Recently, we constructed replication-defective (Reddy et al., 1999b) and replication-competent recombinant BAV-3 (Zakharatchouk et al., 1998; Baxi et al., 1999) expressing BHV-1 glycoprotein gD. Immunization of cattle with these recombinant BAV-3 expressing BHV-1 gD (BHV-1gD) induced a protective immune response against challenge with BHV-1 (Zakhartchouk et al., 1999) . The use of recombinant BAV-3 for expression of vaccine antigen has an inherent advantage over the other available systems, since BAV-3 in a natural pathogen of the cattle. In addition, it has been shown that, even in the presence of BAV-3-specific preexisting antibodies, the recombinant BAV-3 expressing BHV-1 gD was able to induce specific immune responses against both gD and BAV-3. These results strongly suggest that the presence of vectorspecific antibodies should not hinder the use of recombinant BAV-3 vectors for immunization in calves (Zakhartchouk et al., 1999) .
Here, we describe the construction and characterization of replication-competent (E3-deleted) recombinant BAV-3 expressing either natural or synthetic E2 glycoprotein of BVDV. In addition, we demonstrate that intranasal immunization of cotton rats with these recombinant viruses induces BVDV E2-specific mucosal and systemic immune responses.
RESULTS

In vitro translation and immunoprecipitation of BVDV E2 protein
In BVDV-infected cells, the E2 glycoprotein is produced as a result of proteolytic cleavage of the large polyprotein encoding the glycoproteins E ms , E1, and E2 (Collet et al., 1988a,b) . Since the E2 glycoprotein lies at the 3Ј end of the precursor polyprotein, it has its own transmembrane anchor at the 3Ј end, but lacks the signal sequence at its 5Ј end. To allow the proper intracellular processing and transport of the E2 glycoprotein, the signal sequence of BHV-1 glycoprotein gD (Tikoo et al., 1990) was fused in frame to the 5Ј end of the E2ori (E2 original) or E2syn (E2 synthetic) open reading frames. The identity of the modified E2 ORFs was verified by dideoxynucleotide sequencing. To determine whether the gD signal sequence was functional, two in vitro expression plasmids, pSP64-331 and pSP64-338, were generated in which the coding sequence of the E2ori or E2syn, respectively, was placed downstream of the SP6 promoter. In vitro translation of pSP64-331 and pSP64-338 in vitro transcribed mRNA resulted in the synthesis of a 44-kDa polypeptide (Fig. 1a, lane 1; Fig. 1b, lane 4) , which was recognized by E2-specific antisera. In the presence of canine microsomal membranes (Fig. 1a , lane 2; Fig. 1b , lane 5), two polypeptides of 53 and 42 kDa were detected. Treatment of the E2 protein synthesized in the presence of microsomal membranes with EndoH resulted in the detection of only the 42-kDa protein (Fig. 1a, lane 3; Fig. 1b, lane 6) . Taken together, these results suggested that the gD signal sequence of the modified E2 protein is cleaved after directing the E2 into the microsomal membranes for the addition of N-linked highmannose oligosaccharides.
Construction of recombinant viruses
Initially, we assumed that expression of genes from the cytoplasmic-replicating RNA viruses by recombinant E3-deleted BAV-3 would be similar to DNA virus genes . Therefore, we constructed an E3-deleted full-length BAV-3 genomic clone (pFBAV339) containing the BVDV E2ori coding sequence (devoid of any exogenous transcriptional element) inserted in the E3 region in the same transcriptional orientation as E3. Transfection of fetal bovine retina cells with PacI-digested pFBAV339 DNA resulted in the development of cytopathic effects. The recombinant virus was named BAV339. Restriction enzyme analysis of the recombinant virion DNA suggested that recombinant BAV339 contained the E2ori gene (data not shown). However, immunoprecipitation analysis of BAV339-infected cells showed little E2 glycoprotein at early time points and none at later time points postinfection (p.i.) (Fig. 2b) . Since in vitro transcribed mRNA directed the synthesis of E2 glycoprotein (Fig. 2a) , we assumed that failure to detect E2 glycoprotein may be the result of aberrant splicing or instability of E2 glycoprotein transcripts in the nuclei of BAV339-infected cells.
To express more of the E2 glycoprotein, we constructed two full-length BAV-3 genomic clones containing either an E2syn gene (pFBAV331: E2syn gene nucleotides modified relative to the natural E2 gene, to remove the internal cryptic splice sites) or an E2ori gene under the control of a human cytomegalovirus (HCMV) immediate early (IE) promoter (pFBAV338) inserted in the E3 region of pFBAV302 . Both plasmids have the E2 glycoprotein in the same orientation as E3 (Fig. 3) . Since the E2ori gene contains a unique EcoRV restriction enzyme site and E2syn contains two EcoRV sites (Fig. 3) , we digested the plasmid DNAs with EcoRV. As expected, compared to pFBAV302 (Fig. 4, lane a) , EcoRV restriction enzyme digestion of pFBAV331 (Fig. 4 , lane b) and pFBAV338 (Fig. 4 , lane c) produced three and two bands, respectively. Transfections of fetal bovine retinal cells (FBRC) with PacI-digested pFBAV331 or pFBAV338 plasmid DNAs produce cytopathic effects within 15 days. Infected monolayers were freeze-thawed and recombinant viruses named BAV331 (pFBAV331) and BAV338 (pFBAV338) were plaque-purified and propagated on Madin-Darby bovine kidney cells (MDBK). The viral DNA was extracted and analyzed by agarose gel electrophoresis after digestion with EcoRV. As expected, the BAV331 (Fig. 4 , lane e) and BAV338 (Fig. 4 , lane f) genomes contained four and three bands, respectively, compared to the BAV302 (BAV302: wild-type BAV3 with the E3 region deleted; Fig. 4 , lane d) genome, which contained only two bands. This suggested that recombinants BAV331 and BAV338 contained the E2 gene, which was confirmed by Southern blot analysis (data not shown).
Growth of recombinant BAV-3
The growth kinetics of the three recombinant viruses BAV302, BAV331, and BAV338 were analyzed in MDBK cells. Cultures of MDBK cells were infected with the viruses and cells harvested at 6, 12, 24, 36, 48, and 72 h postinfection. Virus in each sample was released by freeze-thawing and titered on MDBK cells. The results indicated a slight reduction in the yield of BAV331 virus at 24 and 36 h postinfection compared to that of BAV302 and BAV338 (Fig. 5) . However, the final yields of all three viruses at later times postinfection were nearly equivalent and approached 10 8 TCID 50 /ml.
Expression of E2 by BAV331 and BAV338
To identify BVDV E2-specific polypeptide expressed by the recombinant viruses, MDBK cells were infected with recombinant BAV302, BAV331, or BAV338 and metabolically labeled with [ 3 H]glucosamine at 12, 18, 24, and 36 h postinfection. To monitor the expression of E2, infected cell lysates were immunoprecipitated with E2-specific monoclonal antibody (Paton et al., 1992) . The immunoprecipitated proteins were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE). A 53-kDa protein ( Fig. 6b) conditions. This suggests that recombinants BAV331 and BAV338 expressed the E2 protein in vitro and the E2 protein existed as a homodimer in the infected cells.
Immune response in cotton rats upon immunization with recombinant viruses
Cotton rats have been described as a useful smallanimal model for studying the pathogenesis and immunogenicity of BAV-3 (Mittal et al., 1996) . To determine the ability of BAV-3 recombinants to induce E2-specific immune responses, cotton rats were inoculated twice intranasally, 3 weeks apart, with 10 7 plaque-forming units (PFU) of BAV302, BAV331, or BAV338. Serum, lung washes, and nasal washes were collected for analysis of IgG and IgA antibodies, whereas lungs were collected for analyzing the number of IgA antibody-secreting cells (ASC). Immunization with BAV331 and BAV338 induced higher IgA antibody response in lung and nasal washes than did immunization with BAV302 (Figs. 7a and 7b ). Immune responses increased significantly (P Ͻ 0.05) following booster immunization with BAV331 and BAV338. E2-specific ASCs were found in the lungs of BAV331-and BAV338-immunized cotton rats and the number of ASC was significantly (P Ͻ 0.05) higher in the BAV338-immunized group than in the BAV331-and BAV302-immunized groups (Fig. 7c) .
Cotton rat sera were assayed for BVDV E2-specific antibodies in an indirect ELISA. Figure 7d shows that the IgG response to BVDV E2 protein was significantly (P Ͻ 0.05) higher in groups immunized with BAV331 and BAV338 than in the group immunized with BAV302. The BAV338-immunized group gave a significantly (P Ͻ 0.05) higher IgG antibody response than did the BAV331-im- munized group. The recombinants also induced BAV-3-specific IgG antibody response (Fig. 7e) , which was not significantly different among the groups. Sera were also tested for BVDV-neutralizing antibodies. Figure 7f shows that immunization with BAV331 and BAV338 recombinant viruses generated BVDV-neutralizing antibodies against BVDV (Singer strain). The neutralizing ability of antibodies generated after immunization with BAV338 was significantly (P Ͻ 0.05) higher than that of the BAV331-immunized group.
DISCUSSION
Recent advances in our ability to identify specific proteins involved in the induction of protective immune responses, combined with developing novel and economical delivery systems, have laid the foundation for the development of new, more efficacious viral vaccines. Recently, recombinant human adenovirus has been used as a delivery vehicle for BVDV vaccine antigens (Elahi et al., 1999b,c) . Since use of human adenoviruses as a vaccine delivery system in domestic animals is limited, we have been attempting to develop species-specific adenovirus as a delivery system for animal vaccination (Zakhartchouk et al., , 1999 . In this report, we describe the construction and characterization of replication-competent BAV-3 expressing BVDV E2 glycoprotein and testing their ability to induce mucosal and systemic immune responses in cotton rats.
Foreign genes were previously inserted in E1 (Reddy et al., 1999b) , E3 , or between E4 and the right ITR (Baxi et al., 1999) of the bovine adenovirus 3 genome. We chose the E3 region for BVDV E2 gene insertion based on the following observations: (i) the BAV-3 E3 region is nonessential and can be replaced with a foreign gene , (ii) E3-deleted BAV-3 grows to high titers , and (iii) the antigens expressed from the E3 region of BAV-3 induce protective immune responses in animals (Zakhartchouk et al., 1999) . However, our initial attempts to express BVDV E2ori gene proved unsuccessful. The insertion of BVDV E2 ORF in the E3 region of BAV-3 resulted in the recovery of recombinant virus (BAV339), although the expression of the E2 protein was very low. One reason could be the presence of internal cryptic splice sites in E2ori, which could result in the synthesis of inappropriate mRNAs in the nucleus. However, insertion of an intron upstream of E2ori did not alter the expression of the protein (data not shown), although a similar approach was successful in obtaining desirable expression of bovine corona virus E3 glycoprotein in the E3 region of BAV-3 (Reddy et al., 2000) . Alternatively, it is possible that the transcripts are unstable in the nucleus (Kühnle et al., 1998) . To enhance the expression of E2 protein, two different approaches were used. One of the approaches to increase the expression of foreign gene was to identify the splice-donor consensus sequences (Mount, 1982) and alter the codons to remove these sequences from the ORFs. To achieve this goal, the E2 ORF was resynthesized by changing the nucleotide sequence, which helped to remove the splice-donor consensus sequences from the E2 sequence. The recombinant virus thus generated from this synthetic E2 (BAV331) expressed E2 protein in appreciable amounts, as shown by immunoprecipitation with E2-specific monoclonal antibodies. This suggests that the presence of internal splice sites affects the proper processing of the E2-specific transcripts. Previously, a similar approach was used successfully to express the BRSV G and BVDV E2 antigen in BHV-1 (Kühnle et al., 1998; Schmitt et al., 1999) .
The second approach used to increase the expression of E2 protein was to insert a heterologous promoter 5Ј to the E2 gene. Insertion of HCMV IE promoter upstream of the E2 ORF (BAV338) resulted in the expression of a desirable amount of E2 protein. This suggests that different approaches have to be explored for the optimization of expression of a foreign gene in the E3 region of BAV-3.
Since BVDV E2 glycoprotein does not contain a signal sequence at the 5Ј end, the BHV-1 gD signal was fused in frame at the 5Ј end of the E2 ORF, for proper intracellular transport and processing of E2 glycoprotein. Immunoprecipitation studies with E2-specific monoclonal antibodies suggest that the E2 glycoprotein was processed through the proper pathway upon insertion of the signal sequence in both recombinant viruses, BAV331 and BAV338. In addition, the recombinant E2 exhibited a 53-kDa molecular mass and appeared to form a 94-kDa homodimer. Similar migration patterns of the monomeric and homodimeric forms of the E2 glycoprotein were observed in the BVDV-infected cells (Weiland et al., 1990) .
Cotton rats were developed as a useful small-animal model for investigating the pathogenesis of BAV3 infection, as well as immune response to BAV3 recombinant viruses (Mittal et al., 1996) . Intranasal immunization of cotton rats with BAV331 and BAV338 recombinant viruses generated E2-specific mucosal and systemic immune responses. In our study, immunization with BAV338 produced neutralization titers in cotton rats that varied from 1/128 to 1/1024, 16 days following booster immunization. Although mice immunized with recombinant fowl pox virus (Elahi et al., 1999a) or with a DNA vaccine (Harpin et al., 1997 (Harpin et al., , 1999 , expressing E2 glycoprotein induced E2-specific immune responses, the neutralization titers were low with recombinant fowlpox virus (1/10 to 1/32) or with DNA immunization (1/10 to 1/128). These results suggest that BAV338 might be able to generate a protective immune response upon challenge in cattle.
Recombinant BAV338 induced a higher IgA response on the mucosal surfaces of lung and nasal tract than did recombinant BAV331. Similarly, higher E2-specific IgG and BVDV-neutralizing titers were observed in the serum of cotton rats immunized with BAV338 than with BAV331. Because cotton rats support only limited replication of BAV-3 (Mittal et al., 1996) , consequently E2 expression may be limited in BAV331-infected cotton rats, since BAV331 uses the homologous BAV-3 E3/MLP promoter. In contrast, since BAV338 contains E2 under the control of a constitutive HCMV IE promoter, the E2 may be expressed for a longer duration in vivo, which could be responsible for induction of a strong immune response. Another reason for induction of weak response by BAV331 may be that the synthetic E2-containing mRNA is less stable than that of the natural E2 gene. However, the RNA studies carried out using the synthetic genes for G and E2 glycoproteins of BRSV and BVDV, respectively (Kühnle et al., 1998; Schmitt et al., 1999) , show that the transcripts generated from these genes are fairly stable. Further RNA and protein expression studies need to be carried out to explore the various possibilities.
An effective vaccine to protect against the mucosal (respiratory and enteric) pathogens will be the one that induces protective immunity in the form of secretory IgA antibodies at the mucosal surfaces/site of entry of the pathogen. Since BVDV initiates infection at the mucosal surfaces, primarily the respiratory tract (Bolin, 1990) , the observed induction of E2-specific IgA responses in the lung and nasal passages of cotton rats and the presence of ASC cells in the lungs after immunization suggests that the recombinant BAV-3 may be good vaccine candidates for protection of animals from infection by BVDV.
In conclusion, we described the construction of recombinant bovine adenovirus vectors expressing glycoprotein E2 of BVDV and showed that intranasal immunization of cotton rats with replication-competent BAV-3 expressing E2 can induce antigen-specific mucosal and systemic immune responses. This work demonstrates the potential of recombinant bovine adenovirus as a live viral vector vaccine for the control of BVDV.
MATERIALS AND METHODS
Cells and viruses
The WBR-1 strain of BAV-3 was cultivated in MDBK. MDBK and fetal bovine retina cells (FBRC) were grown in Eagle's minimum essential medium (MEM) supplemented with 10% fetal bovine serum. The viral DNA was extracted from virus-infected monolayers by the method of Hirt (1967) .
Construction of recombinant plasmids
Construction of plasmid pFBAV338 and pFBAV339. A BglII-digested 1129-bp PCR fragment was isolated from the NADL strain of BVDV by using oligonucleotides (1) Primer 1: 5Ј-AGATCTATGACTTGGATTGCAAACCTG-3Ј and (2) Primer 2: 5Ј-AGATCTTGACTTCTGTTCTGATAAGACC-3Ј and was ligated to BglII-digested pSL301 plasmid, to create plasmid pSL301.E2. A 1097-bp NcoI-EcoRI fragment of plasmid pSL301.E2 was isolated and ligated to 83-bp complementary oligonucleotides [(a) 5Ј-CATGGAAGGGCCGACATTG-GCCGTGCTGGGCGCGCTGCTCGCCGTTGCGGTGAGCTT-GCCTACACACTTGGATTGCAAACCTG-3Ј; (b) 5Ј-AATTCAG- GTTTGCAATCCAAGTGTGTAGGCAAGCTCACCGCAA-CGGCGAGCAGCGCGCCCAGCACGGCCAATGTCGGCCC-TTC-3Ј (encoding the N-terminal 20 amino acids of BHV-1 glycoprotein gD containing signal sequence and N-terminal 6 amino acids of mature E2)], to create plasmid pSig.E2. A T4 polymerase-treated 1.18-kb NcoI-BglII fragment of pSig.E2 was isolated and ligated to either T4-treated HindIII-XhoI-digested polyCMV, to create plasmid pCMV.E2 or SrfI-digested pBAV301, to create plasmid pBAV301.E2. A 1722-bp T4-treated BamHI-BglII fragment of pCMV.E2 was ligated to SrfI-digested pBAV301, to create plasmid pBAV301.cE2. The recombinant BAV-3 genome containing E2 (pFBAV339) or E2 under the control of an HCMV promoter (pFBAV338) was generated by homologous DNA recombination in E. coli BJ5183 between SrfI-linearized pFBAV302 and a 3473-bp XhoI-XbaI fragment of pBAV301.E2 or SrfI-linearized pFBAV302 and a 4015-bp XhoI-XbaI fragment of pBAV3.cE2.
Construction of plasmid pFBAV331. A 3605-bp NcoIMluI fragment of plasmid pBSK-BVDV (containing a synthetic E2 gene; Bayer AG, Germany) was isolated and ligated to 68-bp oligonucleotides (5Ј-CATGGAAGGG-CCGACATTGGCCGTGCTGGGCGCGCTGCTCGCCGTT-GCGGTGAGCTTGCCTACGCGT-3Ј) (Tikoo et al., 1990) , to create plasmid p329a. Plasmid p329a was linearized by MluI and ligated to MluI-digested 474-bp PCR fragment (Primer 3: 5Ј-CGACGCGTCTCGATTGCAAACCTGACTT-3Ј; Primer 4: 5Ј-GGGGAAACGCGTTTATATGTCCG-3Ј), to create plasmid p329b. Finally, a T4-treated 1225-bp NcoI-BamHI fragment was ligated to SrfI-digested pBAV301 to create plasmid pBAV301.E2syn. The recombinant BAV-3 genome containing a synthetic E2 gene (pFBAV331) was generated by homologous recombination in E. coli BJ5183 between SrfI-linearized pFBAV302 and a 3518-bp XbaI-XhoI fragment of pBAV301.E2syn.
Transfection of cells
FBRC were grown in 60-mm dishes in MEM medium with 10% FBS. Cells were transfected with 10 g of PacI-digested pFBAV331 or pFBAV338 recombinant plasmid DNA using the Ca ϩ2 -phosphate method (Hermiston et al., 1998) . Following transfection, cells were maintained in MEM containing 2% FBS at 37°C for 15-20 days until cytopathic effects appeared. Cells showing 50% cytopathic effects were harvested and freeze-thawed three times, and recombinant virus was plaque-purified on MDBK cells .
In vitro transcription/translation
Plasmid DNA (1 g) (pSP64-331, pSP64-338, or pSP64-339) was in vitro transcribed with SP6 polymerase as described by the supplier (Promega, Madison, WI). RNA was translated in vitro for 2 h at 30°C using a rabbit reticulocyte lysate containing 20 Ci [
35 S]methionine. After synthesis, the in vitro translated proteins were analyzed on SDS-PAGE with or without immunoprecipitation. To carry out enzymatic treatment, immunoprecipitated proteins were eluted from protein A-Sepharose in 0.5% SDS and digested with EndoH as described previously (Tikoo et al., 1993) . The digested proteins were finally analyzed on SDS-PAGE gel.
Immunoprecipitations
Monolayers of MDBK cells were infected with 10 PFU of recombinant or wild-type virus. After 90 min of absorption, cells were washed and incubated in MEM containing 2% FBS. At different times p.i., the cells were incubated in glucose-free Dulbecco's modified Eagle's medium (DMEM) for 1 h before labeling with [ 3 H]glucosamine (100 Ci/ml). After 12 h of labeling, cells were washed with PBS and stored at Ϫ70°C. All the samples were analyzed at the same time by harvesting the cells in radioimmunoprecipitation buffer (RIPA buffer: 150 mM NaCl, 10 mM Tris [pH 7.8], 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS). Immunoprecipitations were carried out with monoclonal antibodies against E2 (Paton et al., 1992) and complexes were captured with protein A-Sepharose beads. Precipitates were washed in RIPA buffer and proteins were separated on a 10% SDS-PAGE. Labeled proteins were visualized by autoradiography.
Animal experiment
Four-to 6-week-old cotton rats of either sex were divided into three groups of nine animals each. After anesthetizing the cotton rats with halothane, animals were immunized twice at Day 1 and Day 21 by the intranasal route with 50-100 l of inoculum containing 10 7 PFU of individual recombinant virus. Blood samples were also collected at Days 1, 21, and 37 after primary immunization to examine for the development of BVDV-E2-specific antibody response by enzyme-linked immunosorbent assays (ELISA) and by virus neutralization (VN) assays. Four animals in each group were killed at Days 21 and 37 after primary inoculation by an overdose of halothane. The lungs and nasal secretions were collected separately for analysis of BVDV-E2-specific mucosal IgA responses by ELISA. The lungs were also collected at Days 21 and 37, to determine the frequency of BVDV-E2-specific IgA antibody-secreting cells by ELISPOT.
Preparation of lymphocytes from the lungs
The lungs were removed aseptically, chopped, and incubated in complete medium containing MEM supplemented with 10% FBS, 2 mM L-arginine, 1 mM sodium pyruvate, 100 M nonessential amino acids, 10 mM HEPES buffer, 100 U/ml penicillin G, 100 g/ml streptomycin solution, 150 U/ml collagenase A, and 50 U/ml DNase I for 1 h. The homogenized suspension was then gently passed through a plastic mesh with a 5-ml syringe plunger and washed with MEM. Finally, the lymphocyte population was separated by centrifugation of the lung suspension on a discontinuous Percoll gradient. The cells were washed with MEM, resuspended in complete medium, and incubated for 1 h in a tissue-culture flask to attach adherent cells. The nonadherent cell population was then resuspended and used in the ELISPOT assay.
Antigen-specific ELISPOT assay
Antigen-specific ELISPOT assays were carried out as described previously (Papp et al., 1997) . Briefly, nitrocellulose-based, 96-well microtiter plates were coated with purified BVDV E2 (1 g/well) in coating buffer (50 mM NaHCO 3 /Na 2 CO 3 , pH 9.6) at 4°C overnight. The plates were washed with sterile PBS and further incubated for 1 h at room temperature in complete medium. Lymphocytes were added at a concentration of 1 ϫ 10 6 cells in 100 l/well and incubated overnight at 37°C. Following incubation, cells were first washed with sterile water, then with PBS containing 0.05% Tween-20 (PBST). Biotinylated anti-rat IgG (Zymed Laboratories, San Francisco, CA) or rabbit anti-rat IgA followed by biotinylated goat anti-rabbit secondary antibodies were used for the detection of antigen-specific IgG or IgA. All plates were further incubated with streptavidin-alkaline phosphatase, followed by spot development with 5-bromo-4-chloro-3-indolyl phosphate (BCIP)-nitro blue tetrazolium (NBT) substrate.
Antigen-specific ELISA
The levels of antibodies specific for BVDV E2 in sera, lung, and nasal washes was determined by ELISA. Immunolon-2 microtiter plates were coated with purified E2 (0.6 g/well) in coating buffer at 4°C overnight. The plates were washed with PBST between each step. All samples were serially diluted in PBST-BSA and incubated overnight at 4°C. Antigen-specific IgG was detected by horseradish peroxidase-conjugated goat anti-rat IgG (Cedarlane Laboratories, Hornby, Ontario, Canada). Antigen-specific IgA was measured by rabbit anti-rat IgA, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG. Reactions were visualized with streptavidin-alkaline phosphate conjugate and BCIP/NBT.
Serum neutralization assay
Twofold serial dilutions of heat-inactivated sera were incubated with BVDV for 2 h at room temperature in a total volume of 50 l medium. A total of 100 l media was added to the serum/virus mixture and incubated with MDBK cells in 48-well tissue-culture plates. After 1-h adsorption, the mixture was removed and the cells were washed twice with PBS and overlaid with 0.7% lowmelting agarose. Plaques were counted and titers were expressed as reciprocals of the highest antibody dilution that caused 50% reduction in the number of plaques relative to the control wells that were infected with untreated virus.
